Abstract
1-Furan-2-yl-3-pyridine-2-yl-propenone (FPP-3) is an investigatory drug which has a dual inhibitory action on cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). We examined its effect on the pharmacokinetics of warfarin. Three consecutive days of pretreatment with 17 mg/kg of FPP-3 had no significant effect on the pharmacokinetic parameters of warfarin when orally administered to rats. A higher dosage of FPP-3 however, did cause significant changes in the pharmacokinetic parameters of wafarin. The cytochrome P450 activity test demonstrated that the metabolism of R-warfarin was significantly inhibited by FPP-3 while there was little or no inhibition of the metabolism of S-warfarin, which is mainly responsible for its anticoagulant effect. Therefore, it appears that the alteration in the pharmacokinetic parameters of warfarin was due to the inhibitory effect of FPP-3 on the metabolism of R-warfarin. Although there was a significant increase in the plasma concentration, the area under the curve, half life of warfarin, and prothrombin time were not significantly changed. Based on these findings, the pharmacokinetic drug interaction between FPP-3 and warfarin mainly involves R-warfarin and, therefore, this interaction may not be of clinical significance in terms of warfarin-related toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D., Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis.Circulation, 102, 840–845 (2000).
Blank, J., Tucker, A., Sweatlock, J., Gasiewicz, T., and Luster, M., Alpha-Naphthoflavone antagonism of 2,3,7,8-tetrachlo-rodibenzo-p-dioxin-induced murine lymphocyte ethoxyre-sorufin-O-deethylase activity and immunosuppression.Mol. Pharmacol., 32, 169–172 (1987).
Burnier, M., The safety of rofecoxib. Expert Opin.Drug Saf., 4, 491–499 (2005).
Clark, D., Layton, D., and Shakir S., Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.Drug Saf., 27, 427–456 (2004).
Crespi, C., Miller, V., and Penman, B., Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.Anal. Biochem., 248, 188–90 (1997).
Fiorucci, S., Meli, R., Bucci, M., and Cirino, G, Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?Biochem. Pharmacol., 62, 1433–1438 (2001).
Fosslien, E., Cardiovascular complications of non-steroidal anti-inflammatory drugs.Ann. Clin. Lab. Sci., 35, 347–385 (2005).
Jahng, Y., Zhao, L, Moon, Y., Basnet, A., Kim, E., Chang, H., Ju, H., Jeong, T, and Lee, E., Simple aromatic compounds containing propenone moiety show considerable dual COX/ 5-LOX inhibitory activities. Bioorg.Med. Chem. Lett., 14, 2559–2562 (2004).
Joffe, H., Xu, R., Johnson, F., Longtine, J., Kucher, N., and Goldhaber, S., Warfarin dosing and cytochrome P450 2C9 polymorphisms.Thromb. Haemost., 91, 1123–1128 (2004).
Kwan, D., Bartle, W., and Walker, S., The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.J. Clin. Pharmacol., 39, 68–75 (1999).
Lee, E., Ju, H., Moon, T, Lee, E., Jahng, Y, Lee, S., Son, J., Baek, S., and Chang, H., Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor (NF)-kappa B activation in cultured murine macrophages.Biol. Pharm. Bull., 27, 617–620 (2004).
Lee, S., Jeon, T., Basnet, A., Jeong, H., Lee, E., and Jeong, T., Identification of 1-furan-2-yl-3-pyridin-2-yl-propenone, an antiinflammatory agent, and its metabolites in rat liver subcellular fractions.Arch. Pharm. Res., 29, 984–989 (2006).
Schmedtje, J., Ji, Y., Liu, W., DuBois, R., and Runge, M., Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells.J. Biol. Chem., 272, 601–608 (1997).
Shanmugam, S., Lee, E., Lee, S., Jeon, T., Yong, C., and Yoo, B., The Effect of 1-Furan-2-yl-3-pyridine-2-yl-propenone on Pharmacokinetic Parameters of Theophylline.Biol. Pharm. Bull., 29, 1282–1285 (2006).
Takeuchi, K., Tanaka, A., Hayashi, Y, and Yokota, A., COX inhibition and NSAID-induced gastric damage-roles in various pathogenic events.Curr. Top. Med. Chem., 5, 475–486 (2005).
Whelton, A., Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics.Am. J. Ther., 7, 63–74 (2000).
Wolfe, F., Anderson, J., Burke, T., Arguelles, L, and Pettitt, D., Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.J. Rheumatol., 29, 467–473 (2002).
Yacobi, A., Masson, E., Moros, D., Ganes, D., Lapointe, C., Abolfathi, Z., LeBel, M., Golander, Y, Doepner, D., Blumberg, T., Cohen, Y, and Levitt, B., Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.J. Clin. Pharmacol., 40, 826–835 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shanmugam, S., Lee, E.S., Jeong, T.C. et al. The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin. Arch Pharm Res 30, 898–904 (2007). https://doi.org/10.1007/BF02978843
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02978843